On November 22, 2020, the first "Ankylosing Spondylitis Standardized Medical Center (ASSC)" project in China, sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID),

Recently, the study results of HLX02-HV01 (Clinical Trial No.: NCT02581748), a phase 1 clinical trial of Henlius HLX02 HAN QU YOU^® (Trastuzumab, EU trade name: Zercepac^®), were published in Cancer Chemotherapy and Pharmacology, a well-known journal in the field of cancer therapy, and the study was led by Professor Zhang Quanying from the Second Affiliated Hospital of Soochow University. The publication of the results of the HAN QU YOU^® Phase 1 study indicates the recognition of the quality and data of the clinical study by peer review, which is an affirmation of the development level of high-quality biosimilars produced in China.

At this meeting, Henlius for the first time released the Phase 3 study results of its bevacizumab biosimilar HLX04 (recombinant humanised anti-VEGF monoclonal antibody injection), which was developed by the company independently.

At this conference, Henlius released the updated multi-centre Phase 3 clinical study of Trastuzumab 汉曲优? (HLX02, EU brand name: Zercepac?).